| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/17/2022 | — | Maxim Group | Downgrades | Buy → Hold | |
| 10/13/2021 | 1993.51% | Brookline Capital | → $12 | Initiates Coverage On | → Buy |
| 06/29/2021 | 772.3% | Litchfield Hills | → $5 | Initiates Coverage On | → Buy |
Adial Pharmaceuticals Questions & Answers
The latest price target for Adial Pharmaceuticals (NASDAQ: ADIL) was reported by Maxim Group on August 17, 2022. The analyst firm set a price target for $0.00 expecting ADIL to fall to within 12 months (a possible -100.00% downside). 2 analyst firms have reported ratings in the last year.
The latest analyst rating for Adial Pharmaceuticals (NASDAQ: ADIL) was provided by Maxim Group, and Adial Pharmaceuticals downgraded their hold rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Adial Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Adial Pharmaceuticals was filed on August 17, 2022 so you should expect the next rating to be made available sometime around August 17, 2023.
While ratings are subjective and will change, the latest Adial Pharmaceuticals (ADIL) rating was a downgraded with a price target of $0.00 to $0.00. The current price Adial Pharmaceuticals (ADIL) is trading at is $0.57, which is out of the analyst's predicted range.